Peter Bela Illei, M.D.

Headshot of Peter Bela Illei
  • Associate Professor of Pathology

Languages: English, German, Hungarian


Cytopathology, Pathology, Pathology and Laboratory Medicine, Pulmonary Pathology, Transplant Pathology more

Research Interests

Pathology of thoracic diseases; pathology of lung transplantation; Development of biomarkers for thoracic neoplasms. more


The Johns Hopkins Hospital

600 N. Wolfe Street
PATH 406
Baltimore, MD 21287 map
Phone: 410-502-5160 | Fax: 410-614-9556


Dr. Peter Bela Illei is an associate professor of pathology in the Division of Cytopathology at the Johns Hopkins University School of Medicine. His areas of clinical expertise include pulmonary pathology, transplant pathology, cytopathology and lung cancer biomarkers.

Dr. Illei earned his medical degree from University of Pécs School of Medicine. He completed his residency at New York University Medical Center in pathology and performed a fellowship in oncologic pathology and cytopathology at Memorial Sloan Kettering Cancer Center.

Dr. Illei’s research interests include development of novel immunohistochemical and molecular markers for the diagnosis of solid tissue tumors, pathology of lung cancer and mesothelioma, as well as lung transplantation. more


  • Associate Professor of Pathology
  • Associate Professor of Oncology

Departments / Divisions

Centers & Institutes



  • MD; University of Pecs Medical School (1988)


  • Pathology - Anatomic & Clinical; New York University Medical Center (1998)


  • Cytopathology; Memorial Sloan-Kettering Cancer Center (1999)
  • Oncologic Surgical Pathology; Memorial Sloan-Kettering Cancer Center (2000)

Board Certifications

  • American Board of Pathology (Anatomic Pathology) (2000)
  • American Board of Pathology (Cytopathology) (2001)

Research & Publications

Research Summary

Dr. Illei’s research focuses on the immunohistochemical and molecular characterization of lung cancers and mesothelioma.

Selected Publications

View all on PubMed

Illei PB, Wong W, Wu N, Chu L, Gupta R, Schulze K, Gubens MA. ALK Testing Trends and Patterns Among Community Practices in the United States. JCO Precision Oncol. Epub Oct. 8, 2018.

Xing D, Banet N, Sharma R, Vang R, Ronnett BM, Illei PB. Aberrant Pax-8 expression in well-differentiated papillary mesothelioma and malignant mesothelioma of the peritoneum: a clinicopathologic study. Hum Pathol. 2017 Dec 11. [Epub ahead of print]

Illei PB, Belchis D, Tseng LH, Nguyen D, De Marchi F, Haly L, Riel S, Beierl K, Zheng G, Brahmer JR, Askin FB, Gocke CD, Eshleman JR, Forde PM and Ling MT. Clinical mutational profiling of 1006 lung cancers by next generation sequencing. Oncotarget. 5/20/2017 [Epub ahead of print]. 

Illei PB, Rusch V, Zakowski MF, Ladanyi M: Homozygous Deletion of CDKN2A and Co-Deletion of the Methylthioadenosine Phosphorylase Gene in the Majority of Pleural Mesotheliomas. Clin Can Res. 2003 Jun;9(6):2108-13.

Bishop JA, Sharma R, Illei PB. Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol. 2010 Jan;41(1):20-5. Epub 2009 Sep 8.

Activities & Honors


  • Pulmonary Pathology Society First Prize, United States and Canadian Academy of Pathology, 2002
  • Poster Award, International Congress of the International Academy of Pathology, 1996
  • First Prize Young Clinical Investigator, Postgraduate Medical School, 1990


  • International Association for the Study of Lung Cancer (IASLC)
  • Pulmonary Pathology Society (PPS)
  • US-Canadian Academy of Pathology (USCAP)
  • American Society of Cytopathology (ASC)
  • American Society of Clinical Oncology

Patient Ratings & Comments

The Patient Rating score is an average of all responses to physician related questions on the national CG-CAHPS Medical Practice patient experience survey through Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments are also gathered from our CG-CAHPS Medical Practice Survey through Press Ganey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

Is this you? Edit Profile
back to top button